Alterations in the response of leukaemic cells to apoptosisinducing stimuli may account for resistance to chemotherapy and treatment failure, either by disruption of the apoptotic pathway itself or by altered DNA repair; quiescent cells and those with disrupted cell-cycle checkpoints may also display decreased apoptosis. Quiescence can be induced by the differentiation of myeloid cells, and this led us to investigate whether the modulation of drug-induced apoptosis associated with differentiation might be a model for quiescence-associated resistance generally. We have demonstrated that resistance to idarubicin-induced apoptosis increased with greater duration of incubation of HL60 and U937 cells with ATRA and 1,25(OH) 2 D3 and that this protective effect correlated with the degree of G0/G1 accumulation. In addition, the cytoprotective effects held for other classes of cytotoxic drugs with different mechanisms of action to idarubicin. Prolonged exposure to idarubicin or vinblastine was associated with diminution of the protective effect and re-entry of cells into cycle. The full cytoprotective effect was restored by resupplementation with ATRA or 1,25(OH) 2 D3 during exposure to idarubicin, with concomitant persistence of G0/G1 accumulation. Differentiating agents prevented the accumulation of leukaemic cells at the G2/M checkpoint in response to low concentrations of idarubicin. Understanding how differentiating agents modulate these cell-cycle checkpoints, and how quiescent cells evade apoptosis, may allow the development of therapeutic strategies to limit such apoptosisinhibiting effects and maximise cell kill from chemotherapy. Leukemia (2000) 14, 620-628.
Introduction
Acute myeloid leukaemia (AML) is characterised at a cellular level by an imbalance between proliferation and differentiation. [1] [2] [3] Although only a minority of AML blasts are truly clonogenic (most are non-cycling and show little DNA synthesis), 2 they remain in the proliferative pool and gradually accumulate due to decreased cell death as much as increased proliferation. Often inherent in the transformed phenotype is the ability, either constitutive or inducible, to overcome celldeath promoting stimuli, such as cytotoxic chemotherapy, the clinical consequences of which are refractory disease, relapse and death from leukemia. 4, 5 Resistance to chemotherapy often encompasses drugs with diverse mechanisms of action (so-called multiple drug resistance or MDR) and can arise in a number of ways. The first described and best characterised MDR mechanism is that due to upregulation of the P-glycoprotein (Pgp) efflux pump, however, many non-Pgp MDR pathways have been demonstrated, which may co-exist with classical MDR in the same population of cells. [6] [7] [8] More recently it has become clear that alterations in the response to apoptosis-inducing stimuli, either by disruption of the apoptotic pathway itself or by altered DNA repair, may account for resistance to chemotherapy and treatment failure. 9, 10 Quiescent cells and those with disrupted cell-cycle checkpoints may also display decreased apoptosis. 5 This has led to attempts to recruit cells into cycle with haemopoietic growth factors, so as to enhance their sensitivity to drug-induced apoptosis. 11 In vitro data in support of such an effect are conflicting and clinical studies have failed to demonstrate an overall survival benefit in those patients at greatest risk. [12] [13] [14] [15] Quiescence can also be induced by the differentiation of myeloid cells, and Del Bino et al have demonstrated that DMSO-induced exit from cycling is associated with resistance to drug-induced apoptosis. 16 This led us to investigate whether the modulation of drug-induced apoptosis associated with differentiation of myeloid cells might be a model for quiescenceassociated resistance generally.
We have previously demonstrated the cell-cycle dependence of drug-induced apoptosis in AML cell lines following incubation with all-trans retinoic acid (ATRA), 1, 25 dihydroxy vitamin D3 (1,25(OH) 2 D3) and granulocyte-macrophage colony-stimulating factor (GM-CSF). 17 HL60, U937 and KG1 cells each showed decreased idarubicin-induced apoptosis compared with undifferentiated controls, although the pattern of modulation by ATRA, 1,25(OH) 2 D3 and GM-CSF was particular to each cell line. These effects were independent of differentiation per se and of bcl-2 oncoprotein expression, but correlated with modulation of the cell-cycle changes induced by idarubicin.
In the studies presented here, we sought to further clarify factors controlling drug-induced apoptosis following differentiation-associated G0/G1 accumulation. Specifically, we set out to establish whether the phenomenon of cytoprotection against idarubicin following incubation with differentiating agents is seen with other classes of chemotherapeutic drugs and whether these protective effects can be overcome or reversed. In addition, we further studied the relationship between differentiation and cytoprotection. We demonstrate that the resistance to apoptosis increased with greater duration of incubation of HL60 and U937 cells with ATRA and 1,25(OH) 2 D3, that the cytoprotective effects held for drugs other than idarubicin, and that the G2/M checkpoint control was also disrupted in differentiated cells. Prolonged exposure to idarubicin or vinblastine was associated with diminution of the protective effect and re-entry of cells into cycle; the full cytoprotective effect was restored by resupplementation with ATRA or 1,25(OH) 2 D3 during exposure to idarubicin, with concomitant persistence of G0/G1 accumulation.
Methods

Cells and reagents
HL60 and U937 cells were obtained from the European Collection of Animal Cell Cultures (Salisbury, UK). Reagents were purchased from Sigma Chemical Co (Poole UK) unless otherwise stated. Cells were cultured at 37°C with CO 2 enriched to 5% in RPMI, supplemented with 10% foetal calf serum, 2 mM glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. ATRA and 1,25(OH) 2 D3 (the kind gift of Dr Kay Colston, St George's Hospital Medical School, London, UK) were dissolved in ethanol to achieve stock solutions of 1 mM and 20 M, respectively. These were stored at −20°C until required. The final concentration of ethanol in cultures did not exceed 0.001 v/v.
Design of experiments
The model developed used two stages to assess the effect of differentiation therapy on drug-induced apoptosis. Firstly, cells were incubated with either ATRA or 1,25(OH) 2 D3; this phase was initially of variable duration (24, 72 or 120 h) but was later standardised to 72 h. Secondly, ATRA or 1,25(OH) 2 D3-incubated cells and undifferentiated controls were exposed to various cytotoxic drugs and apoptosis was assessed at time points from 2 to 72 h.
Incubation of cells with ATRA or 1,25(OH) 2 D3
Cells in exponential growth were seeded at 0.05 × 10 6 /ml in 25 cm 2 culture flasks (Costar, High Wycombe, UK) and supplemented with 1 M ATRA or 10 nM 1,25(OH) 2 D3; parallel control flasks contained cells supplemented with neither differentiating agent. Cells were harvested after 24, 72 or 120 h, washed, and used for assay of idarubicin-induced apoptosis (see below); cell proliferation was assessed by counting in a Neubauer haemocytometer. Aliquots were analysed for cellcycle profile.
Analysis of cell-cycle profile
Cell-cycle profiles were measured by flow cytometry (EPICS Elite cytometer, Coulter Electronics, Luton, UK). Washed, pelleted cells were prepared using a Coulter DNA-Prep (Coulter Electronics), which uses a non-ionic detergent permeabilisation stage followed by propidium iodide/RNase staining of DNA. Cells were analysed 1 h after processing. Initial gating to exclude doublets was done using peak vs integral red channel signal, such that control HL60 cells gave 2-5% apoptosis, which level is observed morphologically on cytospin preparations. G0/G1, S and G2/M fractions were identified from the resulting cell-cycle profile and apoptosis was measured from the sub-G1 fraction. 18 The DNA content analysis used was non-kinetic and did not allow demonstration of cell-cycle arrest per se, but rather indicated the relative proportion of cells in the various phases of the cell-cycle.
Drug-induced apoptosis
After incubation with ATRA or 1,25(OH) 2 D3, washed cells were incubated with idarubicin (Pharmacia, Milton Keynes, UK) at concentrations of 2, 10 and 50 g/l in 12-well plates (Costar). Cells were seeded at 0.2 × 10 6 /ml in 3-ml volumes and plates included control wells without idarubicin. Assay of drug-induced apoptosis was also performed using daunorubicin 20-500 g/l (Rhone-Poulenc Rorer, West Malling, UK), Leukemia etoposide 5-80 mg/l (Bristol Myers, Hounslow, UK), cytarabine 5-80 mg/l (Pfizer, Sandwich, UK) and vinblastine 2-50 g/l (Sigma). Drug concentrations were chosen to reflect plasma levels attainable in vivo during conventional chemotherapy as closely as possible. Cells were harvested after 24 or 72 h and prepared using the DNA-Prep (as above).
Apoptosis was measured from the sub-G1 fraction of the resulting cell-cycle profile: leukaemic cells in logarithmic growth demonstrated no significant apoptosis (Ͻ5% of cells); idarubicin induced dose-dependent apoptosis in HL60 and U937 cells after 24 h exposure as quantified by flow cytometry (data not shown). Cell death was confirmed by loss of the ability to exclude trypan blue; the apoptotic nature of cell death was confirmed morphologically and by DNA fragmentation using agarose gel electrophoresis. 19 Resupplementation with ATRA or 1,25(OH) 2 D3 during drug-assay phase HL60 and U937 cells were incubated for 72 h with ATRA or 1,25(OH) 2 D3 as previously described. Two aliquots of each treatment group were harvested and washed; one aliquot was used for drug assay as before, whilst the other was resupplemented with the appropriate differentiating agent concurrent with drug exposure. Cell-cycle profile and idarubicininduced apoptosis was measured after 72 h.
DNA extraction and electrophoresis
DNA was isolated from harvested cells using a Puregene DNA isolation kit (Gentra Systems, Minneapolis, USA). Briefly, cells were lysed and treated with RNase, prior to precipitation of protein. DNA is then precipitated by isopropanol and ethanol, before drying and rehydration. Aliquots of DNA were run on 1% agarose gels with appropriate control samples.
Statistical analysis
Results were analysed using paired t-test, ANOVA and Spearman Rank correlation by means of Statistica (StatSoft, Tulsa, OK, USA) and STATA (Stata Corporation, College Station, TX, USA) software.
Results
Growth and cell-cycle profile after incubation with ATRA or 1,25(OH) 2 D3
Both ATRA and 1,25(OH) 2 D3 progressively inhibited proliferation of HL60 cells ( Figure 1 ). ATRA, but not 1,25(OH) 2 D3, inhibited proliferation of U937 cells (data not shown). ATRA and 1,25(OH) 2 D3 induced progressive accumulation of HL60 cells in the G0/G1 phase of the cell-cycle (Figure 1) , with a significantly higher proportion of cells in G0/G1 after 120 than after 24 h incubation; cells not exposed to differentiating agents also accumulated in G0/G1 over the period of incubation although to a lesser degree (data not shown). ATRA induced G0/G1 accumulation in U937 cells, consistent with inhibition of proliferation (data not shown). Incubation of both cell lines with ATRA and 1,25(OH) 2 D3 was associated with the development of morphological and phenotypic characteristics of maturation as previously described. 17 
Idarubicin-induced apoptosis
Incubation of HL60 cells with either ATRA or 1,25(OH) 2 D3 significantly inhibited the ability of idarubicin 50 g/l to induce apoptosis ( Table 1 ). The degree of protection induced by ATRA or 1,25(OH) 2 D3 increased progressively following longer incubation with differentiating agents (idarubicin exposure standardised to 24 h; Table 1 ).
ATRA protected U937 cells from idarubicin-induced apoptosis, but 1,25(OH) 2 D3 did not (Table 1) . Again, the degree of protection increased as the duration of incubation of cells with ATRA was prolonged. Using Spearman Rank correlation analysis, strong negative correlations were observed for both HL60 and U937 cells between the percentage of apoptotic cells after exposure to 50 g/l idarubicin and the proportion of cells in G0/G1 after incubation with ATRA or 1,25(OH) 2 D3: HL60, r s = −0.950, P Ͻ 0.01; U937, r s = −0.8285, P Ͻ 0.01. 
Apoptosis induced by other cytotoxic drugs
We then assessed whether cells rendered resistant to idarubicin by differentiating agents also became resistant to other cytotoxic drugs with ostensibly different modes of action. HL60 cells were rendered resistant to apoptosis induced by daunorubicin, etoposide, cytarabine and vinblastine after incubation with ATRA or 1,25(OH) 2 D3 (Table 2 ). ATRA conferred protection against daunorubicin, etoposide and cytarabine in U937 cells, but did not protect against vinblastine, whilst 1,25(OH) 2 D3 had no protective effect on U937 cells, except against cytarabine (Table 2) .
Prolonged exposure of leukaemic blasts to idarubicin and vinblastine after incubation with ATRA or 1,25(OH) 2 D3
In view of the correlation of apoptosis with G0/G1 accumulation, we postulated that any shift of a population of cells back into cycle might increase its sensitivity to drug-induced apoptosis. We therefore prolonged the drug exposure phase of our experiments. Cells were incubated for 72 h with ATRA or 1,25(OH) 2 D3 following which the differentiating agent was removed. These populations of cells, which would include both differentiated and residual undifferentiated elements, were then exposed to idarubicin or vinblastine for 72 h, compared with 24 h in previous experiments. Cells plated without cytotoxic drug in these experiments again displayed no significant apoptosis (Ͻ5%); ATRA and 1,25(OH) 2 D3 alone did not induce apoptosis in the absence of idarubicin (data not shown). Exposure of control cells to idarubicin for 72 h did not result in significantly increased apoptosis over that seen after 24 h exposure (Figure 2a and b) . It should be noted that the assay used does not allow cumulative assessment of apoptosis, and cells which were frankly apoptotic at 24 h would have disintegrated by 72 h, and thus not have been detected. Interestingly, the protective effect of ATRA on HL60 cells exposed to idarubicin or vinblastine decreased with increasing duration of cytotoxic drug exposure (Figure 2a) . At 24 h, ATRA reduced idarubicin-induced apoptosis by 72% compared with control cells, whereas at 72 h only 49% reduction in apoptosis was apparent, which was not statistically significant. The corresponding figures for vinblastine-induced apoptosis of ATRAincubated HL60 cells were: 24 h, 57% decrease; 72 h, 45% increase.
In U937 cells, the protection afforded by ATRA against ida- Leukemia rubicin-induced apoptosis also decreased over 72 h (Figure 2b) . At 24 h, ATRA reduced idarubicin-induced apoptosis by 58% compared with control cells, whereas at 72 h no significant protective effect was observed. ATRA did not afford any protection of U937 cells against 24 h vinblastine exposure, but increased the degree of apoptosis observed when exposure to vinblastine was extended to 72 h (Figure 2b ). These findings were confirmed by morphological quantitation of apoptosis (data not shown).
Resupplementation with ATRA or 1,25(OH) 2 D3 during exposure to idarubicin
The findings presented in the previous section demonstrate that following removal of the differentiating agents there was a gradual reduction in the level of protection afforded against chemotherapy-induced apoptosis. We observed that this was coupled with a reduction in the proportion of cells in the G0/G1 phase and postulated that resupplementing cells with differentiating agents during the period of drug exposure might maintain cells in G0/G1 and restore the full protective effect of ATRA and 1,25(OH) 2 D3.
ATRA and 1,25(OH) 2 D3 induced accumulation of HL60 cells in G0/G1 over 72 h, as previously shown (Figure 1 ). These populations subsequently showed a decrease in the proportion of G0/G1 cells when incubated in fresh medium without differentiating agents for a further 72 h (Table 3) . Resupplementing cells with the appropriate differentiating agent, after the initial 72 h, prevented this decrease and slightly increased the G0/G1 accumulation seen (Table 3) . A similar pattern was observed in U937 cells although resupplementing cultures with ATRA did not completely prevent a decrease in G0/G1 accumulation ( Table 3) .
Resupplementation of HL60 cells with ATRA or 1,25(OH) 2 D3 (concurrent with idarubicin exposure) increased the protection against idarubicin-induced apoptosis to similar levels as were obtained after 24 h exposure to idarubicin (Figure 3 ). U937 cells showed a similar response to ATRA resupplementation ( Figure 3 ). The percentage of apoptotic cells after exposure to 50 g/l idarubicin and the proportion of cells in G0/G1 for the above groups of cells again showed a significant inverse correlation in HL60 cells: r s = −0.8065, P Ͻ 0.01. 
Cell-cycle effects of low-dose idarubicin
Exposure of undifferentiated HL60 and U937 cells to low-dose idarubicin for 24 h induced little apoptosis: HL60, 2 g/l 5.6 ± 1.3%, 10 g/l 17.3 ± 6.1%, U937, 2 g/l 2.7 ± 0.9%, 10 g/l 7.0 ± 2.1%. We observed that a greater proportion of such cells accumulated in the G2/M phase of the cell-cycle (as quantitated from flow cytometric cell-cycle profiles) after 24 h exposure to low-dose idarubicin (Figure 4 ). This accumulation in G2/M was not permanent, as by 72 h cells had reentered the cell cycle (Figure 5a ). Very few cells became frankly apoptotic even after prolonged exposure to low-dose idarubicin, suggesting that accumulation at the G2/M checkpoint prevented apoptosis rather than acting as a precursor to it. When cells previously incubated with ATRA or 1,25(OH) 2 D3 were examined, we observed that the accumulation of cells in G2/M was attenuated in the same populations of cells which had shown a reduction in drug-induced apoptosis. Both ATRA and 1,25(OH) 2 D3 reduced the proportion of cells in the G2/M phase of the cell-cycle in the absence of idarubicin and attenuated the G2/M accumulation induced by low-dose idarubicin. As with the modulation of idarubicin-induced apoptosis, this effect was seen with both ATRA and 1,25(OH) 2 D3 in HL60, whereas only ATRA had such an effect on U937 cells (Table 4) .
We sought to establish the fate of those cells which had accumulated in G2/M after 24 h exposure to low-dose idarubicin: fewer than half of the control cells induced into G2/M by 10 g/l idarubicin had undergone apoptosis 24 h later, with the proportion of cells in G0/G1 and S phase also increasing (Figure 5a ). Prolonged exposure of ATRA or 1,25(OH) 2 D3 incubated cells to idarubicin was not associated with a substantial increase in G2/M accumulation, confirming that ATRA and 1,25(OH) 2 D3 prevented rather than simply delayed these idarubicin-induced changes (Figure 5b) .
We sought to establish whether cells which underwent apoptosis after 24 h exposure to idarubicin also exhibited G2/M accumulation prior to doing so: undifferentiated U937 cells were briefly exposed to higher doses of idarubicin (0, 10, 50 or 250 g/l for 2, 4 or 8 h). The accumulation in G2/M seen after 24 h at 10 g/l was not apparent after 8 h exposure, 
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Figure 6
Cell-cycle effects of brief exposure of undifferentiated U937 cells to idarubicin: (a) idarubicin 10 g/l; (b) idarubicin 250 g/l. Results shown are mean of n = 3 experiments; error bars denote s.e.m.
although the proportion of cells in S phase had begun to increase (Figure 6a ). Exposure to 50 or 250 g/l idarubicin induced apoptosis after only 8 h exposure, but no G2/M accumulation was seen in these populations of cells at the earlier time-points (Figure 6b and data not shown), indicating that low-dose and high-dose idarubicin have qualitatively different effects on the leukaemic cells studied.
Discussion
In these experiments, incubation of the human myeloid leukaemia cell lines HL60 and U937 with differentiating agents conferred protection against subsequent exposure to apoptosis-inducing chemotherapeutic drugs. We have previously reported that the reduction in drug-induced apoptosis is independent of the differentiated phenotype per se and of bcl-2 oncoprotein expression. 17 In this report we have further characterised the reduction in apoptosis seen on exposure to cytotoxic agents. By variation of the duration of incubation with ATRA or 1,25(OH) 2 D3, we have demonstrated that U937 cells did not exhibit significant protection until 72 h, when G0/G1 accumulation became evident, whereas HL60 cells demonstrated significant G0/G1 accumulation by 24 h with protection already apparent. In our hands, the amount of apoptosis induced by idarubicin was inversely correlated with the proportion of cells in G0/G1. Thus we propose that a reduction in cell death is not observed until cells have begun to accumulate in G0/G1. These results differ from those of Xu et al 20 who showed that incubation of HL60 cells with 1,25(OH) 2 D3 resulted in decreased cell death at 24 h, before G0/G1 accumulation was detectable. In addition, we demonstrated that re-entry of leukaemic cells back into cycle re-sensitises them to the apoptotic effects of cytotoxic drugs, ie the process is not irreversible.
Differentiation of myeloid leukaemic cells is generally associated with cell-cycle arrest in G0/G1 phase, however, these two phenomena may be independent of each other. Previous reports of the modulation of drug-induced apoptosis have used a wide variety of differentiating agents with broadly similar consequences. ATRA, 1,25(OH) 2 D3, DMSO, TPA and PMA have all been shown to confer HL60 cells with resistance to drug-induced apoptosis. 13, 16, [20] [21] [22] [23] Two groups have demonstrated greater protection against drug-induced damage in adherent than non-adherent cells, following incubation with phorbol esters. 22, 23 Whilst neither study included cell-cycle analysis, previous data show that adherence is associated with monocytoid differentiation and G0/G1 arrest. 24 Taken together, these data suggest that it is a common feature of differentiation that confers the protection against druginduced apoptosis, rather than particular features of any of the individual differentiation programmes. We have previously suggested that this phenomenon is a result of G0/G1 cell-cycle arrest per se, although the mechanism by which such cellcycle arrest is determined may differ between differentiation programmes. In the case of ATRA and 1,25(OH) 2 D3 cellcycle arrest is mediated, at least in part, via upregulation of the cyclin dependent kinase inhibitors (CKI), p21 and p27. [25] [26] [27] [28] As both HL60 and U937 cells lack p53 expression, such CKI effects must be mediated via p53-independent pathways. 29, 30 We have confirmed that differentiated HL60 cells are consistently protected against a range of cytotoxic drugs. Previous studies have used physicochemical agents as well as a wide range of chemotherapeutic compounds with differing modes of action and different cell-cycle selectivities to induce apoptosis. 13, 16, [20] [21] [22] [23] The consistent response of HL60 cells to drugs with activity as topoisomerase inhibitors, DNA interchelators, microtubule disruptors and antimetabolites suggests that the mode of action is irrelevant in determining response. Only Zwelling et al 23 have observed a partial disparity between drugs, with PMA protecting against etoposideinduced DNA fragmentation to a greater extent than against mAMSA-induced damage.
U937 cells, which were not used in any of the previous reports, showed a heterogeneous pattern of modulation of drug-induced apoptosis. Both differentiating agents protected against cytarabine-induced apoptosis, whilst neither was effective when cells were exposed to vinblastine. U937 cells have been shown to differentiate in response to ATRA, as well as 1,25(OH) 2 D3, although the differentiation programme is distinct. [31] [32] [33] The disparate results which we observed with exposure to cytarabine may be explained by differential modulation of sphingolipid signal transduction pathways. Recent data have implicated the sphingolipid ceramide in the signal transduction of several apoptotic stimuli, such as TFN␣, ␥IFN and dexamethasone. 34 Other inducers of apoptosis traditionally viewed as DNA-damaging agents may also have sphingolipid components to their transduction: cytarabine increases generation of ceramide by proteolytic cleavage of sphingomyelin, 35 whilst Bose et al 36 have demonstrated ceramide generation during daunorubicin-induced apoptosis, suggesting a non-DNA-based mechanism for the resulting programmed cell death. Protein kinase C (PKC) has been shown to antagonise apoptosis induced by ceramide, and paradoxically, Emoto et al 37 recently demonstrated that cytarabineinduced apoptosis of U937 involves activation of PKC␦.
Two lines of evidence link these events with 1,25(OH) 2 D3 and TPA-induced differentiation of U937: both phenotypic and functional characteristics of differentiation can be abrogated by inhibition of PKC, 38, 39 whilst treatment of undifferentiated U937 cells with cytotoxic agents induced expression of c-jun and activation of PKC␦. 37, 40, 41 Supporting evidence for the role of differentiation of leukaemic cells in modulation of apoptosis is provided by the studies of Ehinger et al, 42 who recently demonstrated that transfection of U937 with a temperature-sensitive murine p53 cDNA induced growth inhibition, G0/G1 arrest and apoptosis. In contradistinction to our findings, these changes were modulated by 1,25(OH) 2 D3 (which increased G0/G1 arrest, whilst maintaining viability) but not by ATRA. Thus the differentiation programme and apoptotic stimulus may determine the response of U937 cells in a way not seen with HL60, possibly by modulation of the relative activities of ceramide and PKC.
Both HL60 and U937 cells responded to low-dose idarubicin with accumulation in the G2/M phase of the cell-cycle, with only a minority of cells entering apoptosis. Such accumulation has been postulated to allow repair of damaged DNA prior to the crucial checkpoint at entry to mitosis. Our data confirm that a minority of these cells subsequently underwent apoptosis, with most resuming cycling through G0/G1 into S phase. The cell-cycle effects of low-and high-dose idarubicin appeared to be determined by qualitatively different mechanisms: we were unable to demonstrate that cells exposed to 50 or 250 g/l idarubicin accumulated in G2/M prior to becoming apoptotic. Presumably higher doses of idarubicin pose an unequivocally lethal apoptotic stimulus to cells such that 'pausing for consideration of repair' is unnecessary. The reduced G2/M accumulation seen with differentiated cells does not exclude the possibility that the chemoresistance of these populations is determined by enhanced DNA repair, but in G0/G1 phase rather than G2/M.
The clinical implications of our findings are complex. It is impossible for any in vitro schedule to exactly mimic in vivo chemotherapy regimens, which complicates the prediction of tumour responses to dual modality therapy. Despite in vitro evidence for reduced drug-induced cell death following ATRA, 13, 17, 21 the accumulating clinical evidence of APL trials is of greater remission induction and reduced relapse with ATRA plus chemotherapy (as opposed to either modality alone). 43 The current United Kingdom Medical Research Council AML trials, AML-12 and AML-14, include randomisations for the treatment of non-M3 AML cases with ATRA. [44] [45] [46] The cited rationale for the use of ATRA in such patients includes the down-regulation of bcl-2 by differentiation with retinoic acid, thus removing a powerful anti-apoptotic influence.
However, suggestions that differentiation therapy should be combined with chemotherapy for non-M3 AML need to be viewed with caution, despite encouraging initial results. 44, 47, 48 We were unable to show a relationship between bcl-2 expression and the degree of protection from apoptosis in our previous study, and furthermore Del Bino et al demonstrated that DMSO-induced reductions in apoptosis preceded changes in bcl-2 expression, which only occurred after 72 h incubation with DMSO. 16, 17 Previous studies which have examined the effect of diffentiating agents on apoptosis have shown the crucial importance of the relative timings of the two treatment modalities: preincubation of AML cells with ATRA, 1,25(OH) 2 D3 or DMSO is associated with cytoprotection on exposure to chemotherapy, whilst treatment with these differentiating agents after chemotherapy potentiates drug-induced DNA damage and cell death. 13, 16, 49 In each case, where differentiation of HL60 cells preceded chemotherapy, apoptosis was reduced, except in the studies of Solary et al 22 who demonstrated protection after incubation with TPA but not with ATRA prior to exposure to topoisomerase inhibitors. The only previous studies to have used cells other than HL60 were our own, using U937 and KG1, and those of McCulloch's group at Ontario Cancer Institute, using locally developed cell lines, OCI-AML, and fresh patient-derived blasts. 13, 17 Both OCI-AML cells and patient samples showed heterogeneous responses to ATRA incubation prior to or following exposure to cytarabine, but these studies did not include cell-cycle analysis.
The heterogeneity of response demonstrated by Yang et al 13 supports an individualistic approach to pre-treatment assessment in AML, as proposed by Banker et al, 50 where patient samples are analysed to predict likely treatment response allowing therapy to be individualised. The demonstration that differentiation of myeloid leukaemic blasts may render them more resistant to drug-induced apoptosis is indicative of mechanisms which may underlie in vivo resistance to chemotherapy, and the associated outcomes of relapse and death from AML. We have demonstrated that various cell-cycle checkpoints are dysregulated in AML cell lines, which may contribute to the responses observed to chemotherapy following differentiating agents. Understanding how differentiating agents modulate these cell-cycle control points may allow the development of therapeutic strategies to limit such apoptosisinhibiting effects and maximise cell kill from chemotherapy.
